Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

Nature Communications

Volumn 4, Issue , 2013, Pages

  Wassman, Christopher D ^a,b,f   Baronio, Roberta ^b   Demir, Özlem ^c,g   Wallentine, Brad D ^c   Chen, Chiung Kuang ^c   Hall, Linda V ^b   Salehi, Faezeh ^a,b   Lin, Da Wei ^b   Chung, Benjamin P ^b   Wesley Hatfield, G ^b,c,d   Richard Chamberlin, A ^c,e   Luecke, Hartmut ^b,c,e   Lathrop, Richard H ^a,b,c,e   Kaiser, Peter ^b,e   Amaro, Rommie E ^a,c,g  

^a Irvine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of California at Irvine   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GOOGLE INC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; PROTEIN P21; PROTEIN P53; 2,2 BIS(HYDROXYMETHYL) 1 AZABICYCLO(2,2,2,)OCTAN 3 ONE; 2,2-BIS(HYDROXYMETHYL)-1-AZABICYCLO(2,2,2,)OCTAN-3-ONE; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; FUSED HETEROCYCLIC RINGS; HETEROCYCLIC COMPOUND; MUTANT PROTEIN; ONCOPROTEIN; OXEPINE DERIVATIVE; STICTIC ACID;

CANCER; DISEASE TREATMENT; DRUG; GENE EXPRESSION; GENETIC ENGINEERING; MUTATION; TUMOR;

ARTICLE; DOSE RESPONSE; HUMAN; HUMAN CELL; MOUSE; NEOPLASM; NONHUMAN; OSTEOSARCOMA CELL; PROTEIN DOMAIN; SCREENING; STRUCTURE ANALYSIS; TUMOR SUPPRESSOR GENE; WILD TYPE; BINDING SITE; BIOLOGY; CHEMISTRY; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; METHODOLOGY; MOLECULAR DYNAMICS; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; REPRODUCIBILITY; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

APOPTOSIS REGULATORY PROTEINS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING SITES; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYSTEINE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MOLECULAR DYNAMICS SIMULATION; MUTANT PROTEINS; OXEPINS; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; REPRODUCIBILITY OF RESULTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

MLCS; MLOWN;

EID: 84879147794     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2361     Document Type: Article

References (60)

1. Olivier, M. et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19, 607-614 (2002). (Pubitemid 34556481)
2. Soussi, T. & Beroud, C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer 1, 233-240 (2001). (Pubitemid 33741898)
3. Joerger, A. C. & Fersht, A. R. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb. Persp. Biol. 2, a000919 (2010).
4. Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006). (Pubitemid 44960417)
5. Selivanova, G. & Wiman, K. G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26, 2243-2254 (2007). (Pubitemid 46536645)
6. Sharpless, N. E. & DePinho, R. A. Cancer biology: gone but not forgotten. Nature 445, 606-607 (2007). (Pubitemid 46232872)
7. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007). (Pubitemid 46232887)
8. Wiman, K. G. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Adv. Cancer Res. 97, 321-338 (2007). (Pubitemid 46528994)
9. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007). (Pubitemid 46232886)
10. Baroni, T. E. et al. A global suppressor motif for p53 cancer mutants. Proc. Natl Acad. Sci. USA 101, 4930-4935 (2004). (Pubitemid 38469180)
11. Baronio, R. et al. All-codon scanning identifies p53 cancer rescue mutations. Nucleic Acids Res. 38, 7079-7088 (2010).
12. Brachmann, R. K., Yu, K., Eby, Y., Pavletich, N. P. & Boeke, J. D. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 17, 1847-1859 (1998). (Pubitemid 28154516)
13. Danziger, S. A. et al. Predicting positive p53 cancer rescue regions using Most Informative Positive (MIP) active learning. PLoS Comput. Biol. 5, e1000498 (2009).
14. Danziger, S. A. et al. Functional census of mutation sequence spaces: the example of p53 cancer rescue mutants. IEEE ACM Transact. Comput. Biol. Bioinform. IEEE ACM 3, 114-125 (2006).
15. Danziger, S. A., Zeng, J., Wang, Y., Brachmann, R. K. & Lathrop, R. H. Choosing where to look next in a mutation sequence space: active Learning of informative p53 cancer rescue mutants. Bioinformatics 23, i104-i114 (2007). (Pubitemid 47248454)
16. Wieczorek, A. M., Waterman, J. L., Waterman, M. J. & Halazonetis, T. D. Structure-based rescue of common tumor-derived p53 mutants. Nat. Med. 2, 1143-1146 (1996). (Pubitemid 26338636)
17. Bykov, V. J., Issaeva, N., Selivanova, G. & Wiman, K. G. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23, 2011-2018 (2002). (Pubitemid 36104953)
18. Bykov, V. J. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282-288 (2002). (Pubitemid 34250107)
19. Bykov, V. J. et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem. 280, 30384-30391 (2005). (Pubitemid 41216221)
20. North, S., Pluquet, O., Maurici, D., El-Ghissassi, F. & Hainaut, P. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol. Carcinog. 33, 181-188 (2002). (Pubitemid 34195199)
21. Reddy, N. L., Hill, J., Ye, L., Fernandes, P. B. & Stout, D. M. Identification and structure-activity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis. Bioorg. Med. Chem. Lett. 14, 5645-5649 (2004). (Pubitemid 39346361)
22. Zache, N. et al. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol. Oncol. 2, 70-80 (2008).
23. Boeckler, F. M. et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl Acad. Sci. USA 105, 10360-10365 (2008).
24. Wilcken, R. et al. Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53. J. Am. Chem. Soc. 134, 6810-6818 (2012).
25. Yu, X., Vazquez, A., Levine, A. J. & Carpizo, D. R. Allele-Specific p53 Mutant Reactivation. Cancer Cell 21, 614-625 (2012).
26. Lambert, J. M. et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15, 376-388 (2009).
27. Wiman, K. G. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29, 4245-4252 (2010).
28. Amaro, R. E., Baron, R. & McCammon, J. A. An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J. Comput. Aided Mol. Des. 22, 693-705 (2008).
29. Cheng, L. S. et al. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J. Med. Chem. 51, 3878-3894 (2008). (Pubitemid 351956517)
30. Malecka, K. A., Ho, W. C. & Marmorstein, R. Crystal structure of a p53 core tetramer bound to DNA. Oncogene 28, 325-333 (2009).
31. Friedler, A. et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl Acad. Sci. USA 99, 937-942 (2002). (Pubitemid 34106614)
32. Kaar, J. L. et al. Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding. Prot. Sci. 19, 2267-2278 (2010).
33. Cho, Y., Gorina, S., Jeffrey, P. D. & Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346-355 (1994). (Pubitemid 24259959)
34. Wang, Y., Rosengarth, A. & Luecke, H. Structure of the human p53 core domain in the absence of DNA. Acta crystallographica. Sect. D Biol Crystallogr. 63, 276-281 (2007). (Pubitemid 46438519)
35. Emamzadah, S., Tropia, L. & Halazonetis, T. D. Crystal structure of a multidomain human p53 tetramer bound to the natural CDKN1A (p21) p53-response element. Mol. Cancer Res. 9, 1493-1499 (2011).
36. Petty, T. J. et al. An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity. EMBO J. 30, 2167-2176 (2011).
37. Canadillas, J. M. et al. Solution structure of p53 core domain: structural basis for its instability. Proc. Natl Acad. Sci. USA 103, 2109-2114 (2006). (Pubitemid 43271631)
38. Velu, C. S., Niture, S. K., Doneanu, C. E., Pattabiraman, N. & Srivenugopal, K. S. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry 46, 7765-7780 (2007). (Pubitemid 47016060)
39. Bullock, A. N. et al. Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl Acad. Sci. USA 94, 14338-14342 (1997). (Pubitemid 28041374)
40. Bullock, A. N., Henckel, J. & Fersht, A. R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19, 1245-1256 (2000). (Pubitemid 30160617)
41. Natan, E. et al. Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer. J. Mol. Biol. 409, 358-368 (2011).
42. Demir, O. et al. Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants. PLoS Comput. Biol. 7, e1002238 (2011).
43. Le Guilloux, V., Schmidtke, P. & Tuffery, P. Fpocket: an open source platform for ligand pocket detection. BMC Bioinf. 10, 168 (2009).
44. Brenke, R. et al. Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics 25, 621-627 (2009).
45. Goh, A. M. et al. Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity. Proc. Natl Acad. Sci. USA 109, 1685-1690 (2012).
46. Vedadi, M. et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl Acad. Sci. USA 103, 15835-15840 (2006). (Pubitemid 44657553)
47. Castrignano, T., De Meo, P. D., Cozzetto, D., Talamo, I. G. & Tramontano, A. The PMDB Protein Model Database. Nucleic Acids Res. 34, D306-D309 (2006).
48. Case, D. A. et al. AMBER 10 (University of California, 2008).
49. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935 (1983).
50. Pang, Y.-P. Novel zinc protein molecular dynamics simulations: steps toward antiangiogenesis for cancer treatment. J. Mol. Model 5, 196-202 (1999).
51. Rodriguez, R., Chinea, G., Lopez, N., Pons, T. & Vriend, G. Homology modeling, model and software evaluation: three related resources. Bioinformatics 14, 523-528 (1998). (Pubitemid 28416766)
52. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta crystallographica. Sec. D Biol. Crystallogr. 66, 12-21 (2010).
53. Hornak, V. et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65, 712-725 (2006). (Pubitemid 44583220)
54. Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 1781-1802 (2005). (Pubitemid 43078511)
55. Wang, J., Wang, W., Kollman, P. A. & Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations. J. Mol. Graph. Model 25, 247-260 (2006). (Pubitemid 44363172)
56. Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 25, 1157-1174 (2004).
57. Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33-38 27-38 (1996). (Pubitemid 26152973)
58. Baron, R. & McCammon, J. A. Dynamics, hydration, and motional averaging of a loop-gated artificial protein cavity: the W191G mutant of cytochrome c peroxidase in water as revealed by molecular dynamics simulations. Biochemistry 46, 10629-10642 (2007). (Pubitemid 47417256)
59. Hess, B., Kutzner, C., Spoel, D. v. d. & Lindahl, E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4, 435-447 (2008).
60. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455-461 (2010).